In brief: Agenix; Cellestis; Prima Biomed; Novogen
Thursday, 14 April, 2005
Agenix (OTC: AGXLY, ASX: AGX) subsidiary, Agen Biomedical has signed an agreement with diagnostics company Axis-Shield under which Axis-Shield will produce a new laboratory assay for deep vein thrombosis and pulmonary embolism. The Axis-Shield assay will use Agen's 3B6 D-dimer antibody, and will be incorporated into Abbott Laboratories' mmunodiagnostic analyser, AxSYM.
Cellestis' (ASX: CST) TB diagnostic Quantiferon TB Gold has been approved for sale in by the Japanese Ministry of Health, Labour and Welfare.
Prima BioMed (ASX:PRR) has appointed Dr John Sime as a non-executive director. Sime was managing director of Beecham Australia and New Zealand for nine years and later SmithKline Beecham Pharmaceuticals Australia and New Zealand. He was also chief executive of the UK BioIndustry Association for six years.
Novogen (ASX:NRT) subsidiary Glycotex has placed 10 per cent of its stock with a US professional investor for US$4 million in a private capital raising. Novogen retains 84 per cent of the company.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
